FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

48 New, Revised PSGs Out

FDA publishes 34 new and 14 revised product-specific guidances to aid in generic drug development.

latest-news-card-1
FDA General

Miller Named Acting Inspections Chief

FDA names Elizabeth Miller acting associate commissioner of the Office of Inspections and Investigations (OII), replacing Michael Rogers, who retired ...

latest-news-card-1
Marketing

FDA Warns Sarfez About Soaanz Promotional Materials

The CDER Office of Prescription Drug Promotion warns Sarfez Pharmaceuticals that promotional materials for its Soaanz edema drug contain false and mis...

Biologics

Covid Vaccine Policy on Boosters and New Trials

FDA commissioner Marty Makary and CBER director Vinay Prasad outline a new regulatory framework for annual Covid-19 booster shots and call for new cl...

latest-news-card-1
Human Drugs

SSRI/SNRI Labeling Changes Sought

The Antidepressant Coalition for Education petitions FDA to change labeling for selective serotonin reuptake inhibitors and serotonin-norepinephrine r...

latest-news-card-1
Human Drugs

FDA Approves Bayers Jivi Antihemophilic Factor

FDA expands its approval of Bayers Jivi for the routine prophylactic treatment of hemophilia A in previously treated adult and pediatric patients aged...

latest-news-card-1
Human Drugs

Panel Wants More U.S. Patient Data on Glofitamab

FDAs Oncologic Drugs Advisory Committee says there are insufficient number of U.S.-treated patients in a clinical trial supporting a supplemental BLA ...

latest-news-card-1
Federal Register

PDUFA Public Meeting for User Fee Reauthorization

Federal Register notice: FDA announces a 7/14 public meeting to discuss proposed recommendations for the reauthorization of the Prescription Drug User...

latest-news-card-1
Federal Register

Generic Drug Fee Program Reauthorization Meeting

Federal Register notice: FDA hosts a 7/11 public meeting on the reauthorization of the Generic Drug User Fee Amendments (GDUFA) for fiscal years 2028 ...

latest-news-card-1
Human Drugs

CGMP Violations in NWL Netherlands Inspection

FDA warns Netherlands-based NWL Netherlands Services about CGMP violations in its production of finished drugs.